05.03.2018 • News

Kolb Closes Acquisition of Elementis Specialties

From left: Tan Sri Lee Oi Hian, CEO of KLK, and Paul Waterman, CEO of Elementis.
From left: Tan Sri Lee Oi Hian, CEO of KLK, and Paul Waterman, CEO of Elementis.

Kolb Distribution, a subsidiary of Kuala Lumpur Kepong Berhad (KLK), completed the acquisition of Delden-based Elementis Specialties Netherlands (ESN) on Feb. 28, 2018. As of this day, ESN is wholly owned by Kolb and renamed to KLK Kolb Specialties.

The acquired business manufactures surfactants and further specialties and will expand the existing Kolb business portfolio in terms of product range and market coverage. The use of the Delden site as another hub for KLK's market penetration strategy will further accelerate growth in the group's downstream chemical specialties business in Europe.

Company contact







From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read